WO2006036406A3 - Live microbial microbicides - Google Patents

Live microbial microbicides Download PDF

Info

Publication number
WO2006036406A3
WO2006036406A3 PCT/US2005/030216 US2005030216W WO2006036406A3 WO 2006036406 A3 WO2006036406 A3 WO 2006036406A3 US 2005030216 W US2005030216 W US 2005030216W WO 2006036406 A3 WO2006036406 A3 WO 2006036406A3
Authority
WO
WIPO (PCT)
Prior art keywords
antimicrobial polypeptide
microbicides
bacteria
live microbial
commensal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/030216
Other languages
French (fr)
Other versions
WO2006036406A2 (en
Inventor
Dean H Hamer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Priority to EP05814101A priority Critical patent/EP1786445B1/en
Priority to AT05814101T priority patent/ATE511848T1/en
Publication of WO2006036406A2 publication Critical patent/WO2006036406A2/en
Publication of WO2006036406A3 publication Critical patent/WO2006036406A3/en
Anticipated expiration legal-status Critical
Priority to US11/710,512 priority patent/US8349586B1/en
Priority to US13/735,638 priority patent/US20130209407A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/36—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/38—Pseudomonas
    • C12R2001/385—Pseudomonas aeruginosa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates, e.g, to a commensal bacterium which can colonize the genitourinary and/or gastrointestinal mucosa, and which, under suitable conditions, secretes a heterologous antimicrobial polypeptide, wherein the secretad antimicrobial polypeptide is effective to inhibit infectivity by, or a pathogenic activity of, a pathogen. In a most preferred embodiment, the antimicrobial polypeptide inhibits HIV infection (e.g., fusion) and/or pathogenis. Also described are preventive or therapeutic compositions comprising the commensal bacteria, and methods to inhibit infectivity and/or pathogenesis, using the bacteria.
PCT/US2005/030216 2004-08-25 2005-08-25 Live microbial microbicides Ceased WO2006036406A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05814101A EP1786445B1 (en) 2004-08-25 2005-08-25 Live microbial microbicides
AT05814101T ATE511848T1 (en) 2004-08-25 2005-08-25 LIVE MICROBIAL MICROBICIDES
US11/710,512 US8349586B1 (en) 2004-08-25 2007-02-26 Commensal strain of E. coli encoding an HIV GP41 protein
US13/735,638 US20130209407A1 (en) 2004-08-25 2013-01-07 Live microbial microbicides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60405104P 2004-08-25 2004-08-25
US60/604,051 2004-08-25
US68837605P 2005-06-08 2005-06-08
US60/688,376 2005-06-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/710,512 Continuation-In-Part US8349586B1 (en) 2004-08-25 2007-02-26 Commensal strain of E. coli encoding an HIV GP41 protein

Publications (2)

Publication Number Publication Date
WO2006036406A2 WO2006036406A2 (en) 2006-04-06
WO2006036406A3 true WO2006036406A3 (en) 2006-05-18

Family

ID=35949951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/030216 Ceased WO2006036406A2 (en) 2004-08-25 2005-08-25 Live microbial microbicides

Country Status (4)

Country Link
US (2) US8349586B1 (en)
EP (1) EP1786445B1 (en)
AT (1) ATE511848T1 (en)
WO (1) WO2006036406A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
US9808517B2 (en) 2012-04-06 2017-11-07 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
US10900043B2 (en) 2014-09-02 2021-01-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating bacterial disease
WO2016036839A1 (en) * 2014-09-02 2016-03-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating gonorrhea
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
GB2588721A (en) 2018-05-11 2021-05-05 Forte Subsidiary Inc Compositions for the treatment of skin conditions
AU2019433065B2 (en) 2019-03-04 2022-08-18 Aurealis Therapeutics AG Chloride-inducible prokaryotic expression system
WO2022194375A1 (en) 2020-03-18 2022-09-22 Numaferm Gmbh Fusion proteins comprising gg repeat sequences
EP3882260A1 (en) * 2020-03-18 2021-09-22 NUMAFERM GmbH Fragments of hlya and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
US20240228553A1 (en) 2021-03-18 2024-07-11 Numaferm Gmbh Fusion proteins comprising gg repeat sequences
EP4339202A1 (en) 2022-09-16 2024-03-20 NUMAFERM GmbH Fusion proteins comprising gg repeat sequences ii

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228297A1 (en) * 2002-03-08 2003-12-11 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5804179A (en) 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
US5356797A (en) * 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
US6180100B1 (en) 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
IT1270123B (en) 1994-10-05 1997-04-28 Dompe Spa PHARMACEUTICAL COMPOSITIONS CONTAINING ENGINEERED MICROORGANISMS AND THEIR USE FOR THERAPY
AU3958895A (en) * 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
FR2747046B1 (en) * 1996-04-05 1998-06-19 Univ Paris Curie NEW PLASMOVIRUS VACCINES
FR2760750B1 (en) * 1997-03-17 1999-05-28 Sanofi Sa HUMAN NEUROTENSIN TYPE 2 RECEPTOR (HNT-R2)
US6399584B1 (en) * 1998-03-18 2002-06-04 Institute Curie Pharmaceutical composition containing ezrin mutated on tyrosine 353
PT956858E (en) 1998-04-30 2002-04-29 Renata Maria Anna Caval Vesely PHARMACEUTICAL COMPOSITIONS CONTAINING LACTOBACILS FOR THE TREATMENT OF VAGINAL INFECTIONS
CN1331700A (en) * 1998-11-16 2002-01-16 基因纬生物技术公司 Method for generating antibodies by vaccination in poultry using polynucleotides
US6365156B1 (en) 1999-04-16 2002-04-02 Osel, Inc. Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
CA2441626A1 (en) * 2001-03-28 2002-10-17 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
JP3722740B2 (en) 2001-11-05 2005-11-30 三菱電機株式会社 Video processing apparatus and video processing method
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228297A1 (en) * 2002-03-08 2003-12-11 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BENINATI C ET AL: "Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 18, no. 10, October 2000 (2000-10-01), pages 1060 - 1064, XP002261610, ISSN: 1087-0156 *
CHANG THERESA L-Y ET AL: "Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 30 SEP 2003, vol. 100, no. 20, 30 September 2003 (2003-09-30), pages 11672 - 11677, XP002371508, ISSN: 0027-8424 *
ECKERT D M ET AL: "MECHANISMS OF VIRAL MEMBRANE FUSION AND ITS INHIBITION", ANNUAL REVIEW OF BIOCHEMISTRY, PALTO ALTO, CA, US, vol. 70, 2001, pages 777 - 810, XP001152929, ISSN: 0066-4154 *
FERNÁNDEZ L A ET AL: "Specific secretion of active single-chain Fv antibodies into the supernatants of Escherichia coli cultures by use of the hemolysin system.", APPLIED AND ENVIRONMENTAL MICROBIOLOGY. NOV 2000, vol. 66, no. 11, November 2000 (2000-11-01), pages 5024 - 5029, XP002371602, ISSN: 0099-2240 *
GIOMARELLI BARBARA ET AL: "The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1.", AIDS (LONDON, ENGLAND) 5 JUL 2002, vol. 16, no. 10, 5 July 2002 (2002-07-05), pages 1351 - 1356, XP002371509, ISSN: 0269-9370 *
KRUGER C ET AL: "In situ delivery of passive immunity by lactobacilli producing single-chain antibodies", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 20, no. 7, July 2002 (2002-07-01), pages 702 - 706, XP002321895, ISSN: 1087-0156 *
KRUIS W ET AL: "Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.", GUT. NOV 2004, vol. 53, no. 11, November 2004 (2004-11-01), pages 1617 - 1623, XP002371510, ISSN: 0017-5749 *
RAO SRINIVAS ET AL: "Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 23 AUG 2005, vol. 102, no. 34, 23 August 2005 (2005-08-23), pages 11993 - 11998, XP002371507, ISSN: 0027-8424 *
REMBACKEN B ET AL: "Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 354, no. 9179, 21 August 1999 (1999-08-21), pages 635 - 639, XP004831404, ISSN: 0140-6736 *
TROMM A ET AL: "The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial.", ZEITSCHRIFT FÜR GASTROENTEROLOGIE. MAY 2004, vol. 42, no. 5, May 2004 (2004-05-01), pages 365 - 369, XP009063168, ISSN: 0044-2771 *
TZSCHASCHEL B D ET AL: "AN ESCHERICHIA COLI HEMOLYSIN TRANSPORT SYSTEM-BASED VECTOR FOR THEEXPORT OF POLYPEPTIDES: EXPORT OF SHIGA-LIKE TOXIN IIEB SUBUNIT BY SALMONELLA TYPHIMURIUM AROA", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 14, June 1996 (1996-06-01), pages 765 - 769, XP002060319, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
US8349586B1 (en) 2013-01-08
ATE511848T1 (en) 2011-06-15
EP1786445A2 (en) 2007-05-23
EP1786445B1 (en) 2011-06-08
US20130209407A1 (en) 2013-08-15
WO2006036406A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
ATE511848T1 (en) LIVE MICROBIAL MICROBICIDES
EP1343811A4 (en) PROCESSES FOR THE PREPARATION OF PURIFIED LIPOPEPTIDES
MXPA05009352A (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections.
WO2005102057A3 (en) Methods for controlling plant pathogens using n-phosphonomethylglycine
EP2368570A3 (en) Compositions and methods related to staphylococcal bacterium proteins
WO2002060458A3 (en) Compositions and method of tissue superoxygenation
EP1719410A4 (en) Method of controlling plant disease damage by using bacillus and controlling agent
DK1442113T3 (en) Mixture of Propionibacterium Jensenii and Lactobacillus SP. with antimicrobial activities for use as a natural preservative system
WO2003091276A3 (en) Compositions and methods of use of peptides in combination with biocides and/or germicides
MXPA99007997A (en) Concentrated disinfectant compositions.
AR118041A1 (en) MEANS AND METHODS TO IMPROVE THE GROWTH AND PERFORMANCE OF PLANTS
JP2013539776A5 (en)
WO2020232471A3 (en) Methods and compositions comprising staphylococcus protein a (spa) variants
EP1639971A4 (en) COMPOSITIONS FOR SKIN PROTECTION
WO2017011730A3 (en) Phenazine derivatives as antimicrobial agents
MXPA05009449A (en) Pyridinium salts, compounds and methods of use.
RU2340669C2 (en) Probiotic strain of lactobacillus casei ferm bp-100059 (ferm p-19443) and its application, preparation of lactobacillus of probiotic action for humans, animals and plants, preventive or therapeutic agent against infection at humans, animals and plants
EP2124976A4 (en) GROWTH INHIBITION AND ELIMINATION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS BY LACTIC ACID BACTERIA
TW200716162A (en) Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria
WO2004098500A3 (en) CARBACEPHEM ss-LACTAM ANTIBIOTICS
RU2001104332A (en) BIOLOGICAL PRODUCT FOR PROTECTION OF PLANTS FROM FUNGAL AND BACTERIAL DISEASES
WO2007092582A3 (en) Neutralization of bacterial spores
NO20014788L (en) A material for lowering the concentration of pathogenic intestinal peptides
WO2009072762A3 (en) Biocontrol agent containing live biological materials, its spraying apparatus and surface sterilization method with the same in preventing and treating pathogenic bacteria infection
ATE308883T1 (en) HERBICIDES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005814101

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005814101

Country of ref document: EP